GLP-1 Dose Tracker: Log Your mg & Titration Schedule
A GLP-1 dose tracker logs which milligram you took on which date and follows your titration — Wegovy 0.25→2.4, Zepbound 2.5→15. See how to track and share it.
109 篇
全部文章 →A GLP-1 dose tracker logs which milligram you took on which date and follows your titration — Wegovy 0.25→2.4, Zepbound 2.5→15. See how to track and share it.
A GLP-1 shot tracker logs each weekly injection — date, rotated site, and missed-dose window for Wegovy, Ozempic & tirzepatide. See exactly how to track a shot.
Choosing an injection tracker app for GLP-1? Here are the must-have features — site-rotation body map, weekly reminders, dose log, missed-dose logic — and why it beats paper.
Oral Wegovy's most common side effects are gastrointestinal — nausea, diarrhea, vomiting, constipation, and abdominal pain — usually mild-to-moderate and worst during dose increases. Because oral Wegovy is the same molecule as injectable Wegovy (semaglutide), it shares the *same* side-effect profile and the *same* serious warnings, including pancreatitis, gallbladder disease, and a boxed thyroid warning.
Orforglipron's most common side effects are gastrointestinal — nausea, diarrhea, constipation, and vomiting — which are dose-dependent, tend to be worst around each dose increase, and usually settle as the body adapts. Rare but serious risks include a boxed warning for thyroid C-cell tumors plus pancreatitis and gallbladder disease, which need urgent medical care.
In clinical trials, retatrutide's most common side effects are gastrointestinal — nausea, diarrhea, constipation, and vomiting — mostly mild-to-moderate and worst during dose escalation. Its triple-agonist design also produces two distinctive signals: abnormal skin sensations (dysesthesia) and a modest heart-rate increase. Retatrutide is investigational and available only through clinical trials — it cannot be prescribed.
A GLP-1 side effect tracker logs each symptom with its severity, timing vs your dose, and food link — so you spot patterns and know when the log says see a doctor.
An oral Wegovy tracker logs your daily dose, the empty-stomach fasting window, weight trend, protein & side effects. Here's what to track on the Wegovy pill.
An orforglipron tracker logs your daily dose, titration step, weight trend, protein & side effects. Learn what to track on Foundayo, the oral GLP-1 pill, and why.
Tirzepatide (Mounjaro, Zepbound) acts on two hormones (GIP + GLP-1) and produced greater average weight loss in trials (~21%) than semaglutide (Ozempic, Wegovy, ~15%). But semaglutide has the longer track record and strong cardiovascular data. The "better" one depends on your goals, tolerance, cost, and prescriber.
The most common GLP-1 side effects are gastrointestinal — nausea, vomiting, diarrhea, constipation, and abdominal pain — and they are usually mild, most likely when starting or increasing the dose, and tend to ease within a few weeks. Rare but serious risks include pancreatitis, gallbladder problems, and severe delayed stomach emptying, which need urgent medical attention.
Without insurance, Ozempic and Wegovy have list prices of roughly $970–$1,350 per month. But almost nobody pays that. Through the manufacturer's cash-pay pharmacy (NovoCare), self-pay prices in 2026 are about $349–$499/month for the injection and $149–$299/month for the newer oral pill — and with commercial insurance plus a savings card, eligible patients can pay as little as $0–$25 a month.
Mounjaro's most common side effects are gastrointestinal — nausea, diarrhea, decreased appetite, vomiting, and constipation — usually mild and worst during dose increases. Many users also report sulfur ("egg") burps. Rare but serious risks include pancreatitis, gallbladder disease, and severe delayed stomach emptying.
A Mounjaro tracker logs your dose date, injection site, weight trend, protein & side effects. Learn exactly what to track on tirzepatide and why it matters.
Ozempic's most common side effects are gastrointestinal — nausea, vomiting, diarrhea, constipation, and abdominal pain — usually mild and worst during dose increases. Rare but serious risks include pancreatitis, gallbladder disease, and severe delayed stomach emptying, which need urgent care.
An Ozempic tracker logs your dose day, injection site, weight trend, blood sugar & side effects. Learn what to track on semaglutide and why it matters.
A retatrutide tracker guide: what the investigational triple agonist is, trial results so far (~24% weight loss in Phase 2), its status, and what you'd track.
Semaglutide's most common side effects are gastrointestinal — nausea, diarrhea, vomiting, constipation, and abdominal pain — usually mild and worst during dose increases. Frequency depends on the product and dose: highest with Wegovy 2.4 mg (weight loss), lower with Ozempic and oral Rybelsus (diabetes). Rare serious risks include pancreatitis, gallbladder disease, and severe delayed stomach emptying.
A semaglutide tracker logs your dose, injection site or pill timing, weight trend, protein & side effects across Ozempic, Wegovy & Rybelsus. Here's what to track.
Looking for a Shotsy alternative on Ozempic or Zepbound? What Shotsy's shot tracker does well, where it stops, and how an all-in-one GLP-1 app compares.
The most common tirzepatide side effects are gastrointestinal — nausea, diarrhea, vomiting, constipation, and abdominal pain — usually mild and worst during dose increases. Rare but serious risks include pancreatitis, gallbladder disease, and severe delayed stomach emptying, which need urgent medical care.
A tirzepatide tracker logs your weekly dose, injection site, weight trend, protein & side effects — for Mounjaro or Zepbound. Learn what to track and why.
Wegovy's most common side effects are gastrointestinal — nausea, diarrhea, vomiting, constipation, and abdominal pain — usually mild and worst during dose increases. Because Wegovy titrates to a higher 2.4 mg dose, these are reported more often than with Ozempic. Rare but serious risks include pancreatitis, gallbladder disease, and severe delayed stomach emptying.
A Wegovy tracker logs your dose date, injection site, weight trend, protein & side effects. Learn exactly what to track on semaglutide and why it matters.
Zepbound's most common side effects are gastrointestinal — nausea, diarrhea, vomiting, constipation, and abdominal pain — usually mild and worst during dose increases. Injection-site reactions and hair loss are also labeled. Rare but serious risks include pancreatitis, gallbladder disease, and severe delayed stomach emptying, which need urgent care.
A Zepbound tracker logs your dose date, injection site, weight trend, protein & side effects. Learn exactly what to track on tirzepatide and why it matters.
GLP-1受体激动剂(Wegovy、Mounjaro、Zepbound)可产生15-22%的平均减重(STEP 1、SURMOUNT-1)。但STEP 4报告停药一年后体重反弹+11.6%p——约78%的减重量返回。WHO(2022)和ADA Standards(2024)明确推荐在药物治疗同时进行行为疗法,STEP 3(JAMA 2021)显示强化行为疗法联合用药的减重效果是标准护理联合用药的近3倍(−16% vs −5.7%)。HAVIT将此结构化为3个阶段——用药前(M0)、适应期(M1)、维持/停药期(M2)——整合药物、肌肉保护和行为学习。HAVIT不开具GLP-1处方;处方、剂量和停药决策仍属医生职责范围。
FDA检测发现30%的复方司美格鲁肽样品存在纯度问题,而品牌Wegovy保持99.5%以上的一致性——但完整的安全图景远比新闻标题复杂得多。
对大多数司美格鲁肽用户来说,少量到适度饮酒(偶尔1-2杯)基本安全。但GLP-1会延缓胃排空,可能放大酒精效果——务必了解自己的耐受度,警惕低血糖风险。
大脑中控制情绪的区域存在大量GLP-1受体,这解释了为什么部分用药者会出现焦虑或情绪波动——好消息是,大多数情况会在8-12周内逐渐改善。
GLP-1药物让胃排空速度减慢30-50%,导致咖啡因吸收变慢但持续时间更长——这篇文章教你重新调整喝咖啡的习惯。
GLP-1药物让胃排空速度降低40%,这意味着可溶性纤维才是你的盟友,而不溶性纤维反而可能帮倒忙——这是有科学依据的调整方案。
GLP-1药物会使肠道蠕动减慢30-40%,需要选择可溶性纤维而非不可溶性纤维,并配合科学的补水时机,而不是照搬普通的便秘建议。
GLP-1药物单独使用很少引起低血糖,但一旦与胰岛素或磺脲类联用,情况就完全不同了——本文教你如何安全调整剂量。
GLP-1药物会重塑大脑的奖赏通路,产生真实的味觉厌恶——这不是简单的食欲下降,而是可以通过策略性方法来管理的神经反应。
GLP-1药物导致的快速减重会打乱胆汁化学平衡,但通过合理摄入脂肪、控制减重速度、预防性使用熊去氧胆酸,可将胆结石风险降低高达80%。
大多数GLP-1类药物引起的胃部不适在8-12周内缓解,但如果持续呕吐、严重腹胀或非预期体重下降超过5%,则提示真正的胃轻瘫,需要及时就医评估。
大多数GLP-1引起的胃部不适会在几周内缓解,但特定警示信号——比如进食6小时后还在呕吐未消化的食物——意味着真正的胃轻瘫,需要立即停药。
GLP-1类药物导致的脱发源于快速减重引发的休止期脱发,而非药物本身——保证足够的蛋白质摄入(每公斤体重1.2-1.5克)可以预防和逆转这一问题。
GLP-1药物导致的脱发通常是快速减重引发的休止期脱发,而非药物本身的问题——大多数人在6-12个月内会看到头发重新长出。
司美格鲁肽等GLP-1药物有内置的"血糖依赖性"安全机制,非糖尿病患者发生真正低血糖的概率极低——临床试验中不到1%。
大多数服用司美格鲁肽的人需要在用药前做基线肾功能检查,之后每3-6个月复查一次。如果胃肠道副作用明显导致脱水,监测频率还要更高。
GLP-1药物会让胃排空时间延长2-4小时,导致左甲状腺素吸收率下降。建议服药后至少等60分钟再进食,调药期间每6-8周复查一次TSH。
每天按1.2-1.6g/kg体重摄入蛋白质,分4餐进食,每餐保证30g以上富含亮氨酸的蛋白质——这比只关注每日总量更能有效保护肌肉。
GLP-1药物会延缓胃排空,而非甾体抗炎药会刺激胃黏膜——两者叠加可能显著增加胃肠道并发症风险,但好消息是有更安全的替代方案。
GLP-1药物可能使口服避孕药的吸收延迟1-4小时,但现有证据表明,只要坚持按时服药,避孕效果基本不受影响。
GLP-1药物引起的胃部不适大多是正常现象,但特定的疼痛模式、发作时间和伴随症状可能预示罕见但严重的胰腺炎——了解这些区别能帮你做出正确判断。
三重激动剂瑞他鲁肽在临床试验中实现24%的减重效果,超越双靶点替尔泊肽(21%)和单靶点司美格鲁肽(15%),但三者的副作用特征各有不同,值得深入了解。
同一个分子,不同的剂量设计——在司美格鲁肽不同品牌之间切换,需要精准把握时机和剂量匹配,否则要么药效断档,要么副作用翻倍。
GLP-1药物的甲状腺监测取决于你的个人和家族病史——大多数人只需要最基本的关注,但某些风险因素会完全改变这一切。
GLP-1类药物在第6个月左右出现平台期是可预测的生理现象——通常是代谢适应在作祟,而非药物失效。针对性干预可以重启减重进程。
使用司美格鲁肽(Wegovy/诺和盈)期间,每天摄入1.2-1.6克/公斤体重的蛋白质,可以最大程度减少肌肉流失。
大多数司美格鲁肽相关的脱发源于快速减重引发的休止期脱发,而非药物本身——在合理营养支持下,通常6-9个月内可自行恢复。
慢速滴定方案(每个剂量维持6-8周,而非标准的4周)可将恶心发生率降低67%,72周时减重效果与标准方案完全一致。
替尔泊肽的胃肠道副作用通常比司美格鲁肽早2-3周缓解,78%的患者在第8周时症状消失,而司美格鲁肽需要到第12周。
最后一针司美格鲁肽后等一周,无论之前用多大剂量,替尔泊肽都从2.5mg起步,预留2-3周适应胃肠道反应。
Wegovy报销成功的关键在于:策略性准备材料、坚持走完申诉流程、吃透你所在保险的具体要求——本文手把手教你怎么做。
GLP-1药物会延缓胃排空并与酒精竞争肝脏酶,导致酒精起效更快、作用更强——大多数患者反映酒量下降了40-60%。
同一个分子,不同的使命:Ozempic用于控糖最高剂量2mg,Wegovy用于减重则达2.4mg。两者在医保报销上被视为完全不同的药物,选错可能意味着自费上千元。
GLP-1类药物会改变肠道血清素的产生并延缓药物吸收,如果你同时服用SSRI或SNRI类抗抑郁药,需要调整服药时间策略。
快速减重——而非GLP-1药物本身——才是骨密度下降的主要原因。针对性的钙+维生素D补充方案可以大幅预防骨质流失。